Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Tag Archive for: Penzberg
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.